<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Moderna Inc. were up 2.3% in premarket trading on Wednesday, the day after the company’s stock price hit an all-time high of $234.60 when the market closed on Tuesday. Moderna has one authorized product, its two-dose, mRNA-based COVID-19 vaccine; the global success of its shot, along with BioNTech and Pfizer Inc.’s COVID-19 vaccine, has opened the door for broader interest in mRNA technology.
...read full article on Market Watch
